The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting
Kasckow J, Mulchahey J, Mohamed S. The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting. Journal Of The American Medical Directors Association 2004, 5: 242-248. DOI: 10.1097/01.jam.0000129822.54487.14.Peer-Reviewed Original ResearchLong-term care settingsOlder patientsAtypical antipsychoticsCare settingsNeurodegenerative disordersSide effectsDouble-blind placebo-controlled trialHigh-potency conventional antipsychoticsLong-term care patientsOpen-label studyPlacebo-controlled trialNewer atypical antipsychoticsOlder patient populationUse of quetiapineUse of risperidoneExtrapyramidal side effectsAtypical antipsychotic medicationsConventional antipsychoticsCare patientsTardive dyskinesiaNovel antipsychoticsAntipsychotic medicationPatient populationPsychopharmacologic agentsAgitation symptomsThe Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting
Kasckow J, Mulchahey J, Mohamed S. The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting. Journal Of The American Medical Directors Association 2004, 5: 242-248. PMID: 15228634, DOI: 10.1016/s1525-8610(04)70130-9.Peer-Reviewed Original ResearchConceptsAtypical antipsychoticsRate of extrapyramidal side effectsHigh-potency conventional antipsychoticsDays of risperidoneAtypical antipsychotic medicationsExtrapyramidal side effectsDay of olanzapineDouble-blind placebo-controlled trialConventional antipsychoticsNovel antipsychoticsAntipsychotic medicationTardive dyskinesiaTreating older patientsPsychopharmacological agentsAgitation symptomsNeurodegenerative disordersAntipsychoticsBehavioral agitationPlacebo-controlled trialOpen-label studyOlder patientsHigh-potencyAripiprazoleOlanzapineRisperidone